Robinson Bradshaw

Month: January 2010

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: Healthcare hacks on the rise. Attacks doubled in Q4 thanks to sensitive data, “large attack […]

Life Technologies Fires Latest Sequencing Salvo

Another week, another drop in the cost of whole-genome sequencing. The latest announcement comes from Life Technologies, which yesterday announced the launch of its SOLiD 4 sequencing system. The details of the announcement are well-covered by GenomeWeb and Matthew Herper of Forbes.com. In brief, the SOLiD 4 generates 100 gigabases of data per run at […]

Raising Private Capital

This commentary in the Genomics Law Report’s ongoing series Bench to Market is contributed by Mark O. Henry, Robinson, Bradshaw & Hinson, P.A. Last week in the Bench to Market series, we discussed the license-out business model as an alternative to raising capital for the commercialization process. Because the business idea is “your baby,” however, […]

Meet the New deCODE, Same as the Old deCODE?

When deCODE genetics declared bankruptcy last fall it made a big splash. Geneticists pondered the future of the Icelandic biotechnology company’s one-of-a-kind genetic database and research platform, while investors and creditors wondered if they were going to be left out in the cold. The initial bankruptcy buzz gave way over the past several months to […]

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: Australia Issues New Privacy Guidelines for Health Practitioners on Disclosing Genetic Information w/o Patient Consent: […]

What ELSI Was New: MagCloud Edition

There are now three ways to review last fall’s guest commentary series, What ELSI is New? You can read the individual commentaries online, download the entire series as a free e-book (pdf) or, by popular demand, order a bound copy of the series through MagCloud. MagCloud allows publishers to create a glossy, bound magazine from […]

GLR Update: In The Battle for Sequencing Supremacy, is 128 > $10,000?

The biggest industry developments last week were being announced at J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco. The Genomics Law Report covered Illumina’s announcement of its new next-generation genomic sequencing machine (Another Stop on the Road to the $1,000 Genome), the HiSeq 2000, which promises to sequence an entire genome in one week […]

GLR Update: The Fate of Follow-On Biologics Remains Uncertain

When the GLR looked last month at the ongoing debate over follow-on biologics, we noted that one of the most contentious issues in creating a regulatory approval pathway for these generic biological drugs centered on the appropriate length of the market exclusivity to be provided to developers of original biologics. Even as we asked the […]

The License-Out as a Business Model

This commentary in the Genomics Law Report’s ongoing series Bench to Market is contributed by Steve Newmark, Robinson, Bradshaw & Hinson, P.A. The drive to create something new and useful is an almost universal trait of entrepreneurs. This passion, however, is not always accompanied by the same enthusiasm for managing the more mundane tasks of […]

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: Patients demand: ‘Give us our damned data’ http://bit.ly/7EYeqQ (CNN, HT @jensmccabe) At present, research subjects […]